Chemistry:CXL-1427

From HandWiki
Revision as of 22:33, 30 December 2021 by imported>TextAI (linkage)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Cimlanod or CXL-1427 is an experimental drug for the treatment of acute decompensated heart failure. It was created by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a nitric oxide donor.[1] CXL-1427 is a prodrug of CXL-1020.[2]

A preliminary study showed efficacy in patients with class III and IV heart failure.[3] A phase II clinical trial was completed in 2016.[4]

References